Review

Treatment of Giant Cell Arteritis (GCA)

Alexis Régent 1,2,* and Luc Mouthon 1,2

1 Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Systémiques Rares d’Ile de France, APHP-CUP, Hôpital Cochin, F-75014 Paris, France; luc.mouthon@aphp.fr
2 Institut Cochin, Université de Paris Cité, F-75014 Paris, France
* Correspondence: alexis.regent@aphp.fr

Abstract: Giant cell arteritis (GCA) is the most frequent primary large-vessel vasculitis in individuals older than 50. Glucocorticoids (GCs) are considered the cornerstone of treatment. GC therapy is usually tapered over months according to clinical symptoms and inflammatory marker levels. Considering the high rate of GC-related adverse events in these older individuals, immunosuppressive treatments and biologic agents have been proposed as add-on therapies. Methotrexate was considered an alternative option, but its clinical impact was limited. Other immunosuppressants failed to demonstrate a significant favourable benefit/risk ratio. The approval of tocilizumab, an anti-interleukin 6 (IL-6) receptor inhibitor brought significant improvement. Indeed, tocilizumab had a noticeable effect on cumulative GCs’ dose and relapse prevention. After the improvement in pathophysiological knowledge, other targeted therapies have been proposed, with anti-IL-12/23, anti-IL-17, anti-IL-1, anti-cytotoxic T-lymphocyte antigen 4, Janus kinase inhibitors or anti-granulocyte/macrophage colony stimulating factor therapies. These therapies are currently under evaluation. Interestingly, mavrilimumab, ustekinumab and, to a lesser extent, abatacept have shown promising results in phase 2 randomised controlled trials. Despite this recent progress, the value, specific condition and optimal application of each treatment remain undecided. In this review, we discuss the scientific rationale for each treatment and the therapeutic strategy.

Keywords: glucocorticoids; immunosuppressant; biologics; treatment; giant cell arteritis

1. Introduction

Giant cell arteritis (GCA) is the most frequent primary large-vessel vasculitis. It typically affects large-sized arteries in people older than 50 years [1]. Ophthalmic, vertebral and external carotid-branch artery involvement is responsible for headaches and most of the ischemic symptoms described during GCA. Subclavian and axillary arteries as well as aorta involvement are now well described, owing to advances in imaging over the years [2]. Relapse rate differs during follow-up according to the initial symptom and/or vascular involvement [3,4]. These different clinical phenotypes might influence therapeutic strategies, although there is no agreement on the relevant examinations that should be performed at the time of diagnosis to identify large-vessel disease extension.

Glucocorticoids (GCs) have been the cornerstone of GCA medical treatment since the 1950s [5]. However, long-term use of GCs is responsible for diabetes, osteoporosis, infections, cardiovascular disease, behavioural effects or cognitive impairment [6]. Additionally, about 86% of patients experience GC-related side effects during follow-up [7,8]. Therefore, immunosuppressant (IS) therapy, including methotrexate (MTX) [9], has been used as an adjunct therapy despite the modest effect on vasculitis control. More recently, biologic agents and, specifically, tocilizumab (TCZ) have had a major effect on preventing relapse and as a GCs-sparing treatment [10]. Despite these alternatives, the optimal therapy for de novo or relapsing disease remains unclear, and recommendations vary among countries and over time [11].
In this review, we discuss the evidence-based data regarding available treatments or future therapeutic options and compare consensus guidelines regarding optimal treatment for GCA [11–14].

2. Glucocorticoids

GCs typically trigger a marked improvement within days [15]. Few studies have specifically focused on GCA initial therapy. In patients without stroke or transient or permanent vision loss, high-dose oral GCs therapy should be started as soon as possible to avoid stroke or visual impairment that may occur at the acute phase of the disease. Indeed, fast-tracked management of suspected GCA has been associated with an 88% reduction in permanent visual loss [16]. Another study confirmed the short-term benefit for sight, with a 2.1-fold higher relative risk of blindness in the conventional treatment group, with no change in long-term prognosis [17]. For uncomplicated disease, results for the use of initial intravenous (IV) GCs are conflicting [18,19]. In a randomised controlled trial (RCT) of 164 patients, 240 mg IV methylprednisolone had no significant long-term GCs-sparing effect [18]. In a smaller study, three methylprednisolone injections of 15 mg/kg/day allowed for a more rapid tapering of oral GCs [19]. In this study, 10 of 14 patients receiving IV GCs were taking <5 mg/day prednisone at 36 weeks as compared with 2 of 13 control patients (p = 0.003). Despite the increased rate of sustained remission, the small size of this RCT does not allow for definitive conclusions, and it is generally accepted that IV methylprednisolone therapy should be avoided in uncomplicated disease [12]. An initial starting dose has been proposed as a fixed dose [11,14,20] or weight-adjusted dose (0.5 or 0.7 mg/kg/day) [12,18], with few comparisons between GC induction schemes. Therefore, recommendations rely on expert opinion rather than strong evidence. Alternate day GC therapy increases the risk of relapse and should be avoided [21].

In patients with ischemic manifestations, methylprednisolone pulse therapy has been proposed to prevent further visual loss. Visual improvement was observed in 7% of 41 patients receiving IV methylprednisolone versus 5% of 43 patients receiving oral GCs (p = 0.672). In this study, early diagnosis and the immediate start of GC therapy were the keys to improvement [22]. The treatment of visual manifestations within the first day predicted improvement in a cohort of 69 patients with GCA and visual involvement [23]. Despite the lack of evidence for an additional effect of methylprednisolone therapy, it is still the preferred option in recent recommendations for GCA with ischemic manifestations [11,14].

GC tapering schemes during GCA have not been extensively studied. Relapses tend to occur more often in patients receiving the fastest GC tapering protocol (40% at month 2 as compared to 20% in the slow tapering regimen group) [24]. Additionally, observational studies found that approximately 50% to 70% of patients achieve GC-free remission after a median follow-up of 2 to 3 years [7,8,25]. A more recent RCT found that 15% of patients on a 6-month GC tapering scheme could achieve GC-free sustained remission [10]. Thus, targeting a daily dose of prednisone of 20 mg/day at month 3, 10 mg/day at month 6 and 5 mg/day at month 12 seems too conservative. In addition, a delayed reduction in GC dose, defined as >10 mg above the target dose, was observed in nearly one-third of patients, and this might be responsible for a high burden of GC-induced side effects [6,26]. Relapses occurred when patients received 5 mg/day prednisone [25], and this low-dose GC therapy is often considered a security dose preventing further relapse.

3. Immunosuppressants

Despite improvement in the side effects prophylaxes, long-term use of GCs is associated with osteoporosis, infection or diabetes, which are a major concern in older individuals. Therefore, IS therapy has been evaluated for reducing patient exposure to GCs, relapse rate, and less frequently, remission induction rate (Table 1). Three RCTs evaluated MTX (7.5–20 mg/week) as an add-on therapy for newly diagnosed disease. These trials found no significant GCs-sparing effect [27] or reduction in relapse rate [28] despite limits (re-
duced dose of MTX in one trial [27] and alternate day GC therapy in another [28]). A third RCT found a reduced relapse rate (45% vs. 84.2%; \( p = 0.02 \)) [29]. Following these conflicting results, an individual patient data analysis suggested hazard ratios for a first and second relapse of 0.65 (\( p = 0.04 \)) and 0.49 (\( p = 0.02 \)), respectively [9]. The real impact of MTX in real life is still debated [30], and a large multicentric RCT evaluating MTX versus TCZ (NCT03892785) is attempting to answer this delicate question. Findings from a small series of patients with relapsing GCA \( (n = 11) \) or polymyalgia rheumatica \( (n = 12) \) treated with leflunomide (LEF) showed a reduction in C-reactive protein level and GC daily dose [31]. Additionally, the results of a retrospective case series of 51 patients receiving LEF or MTX suggested a reduced duration of treatment achieved remission in patients receiving LEF [32]. However, the retrospective nature of the study, the limited size of the population and the rate of side effects must be considered.

In an RCT of relapsing GCA in clinical remission after GC therapy, 31 patients received azathioprine (AZA) as an add-on therapy or a placebo. After a 52-week follow-up, patients receiving AZA received a reduced dose of GCs \( (1.9 \text{ mg/d}} \text{ay vs. 4.2 mg/day, } p < 0.05) \) [33]. Despite the positive result, the modest clinical impact has not changed medical practice, and AZA is rarely used as an additional therapy. Dapsone was found to be effective in addition to GC as a first-line therapy or as a GCs-sparing agent in relapsing GCA [34]. However, patients experienced numerous side effects, including skin rash or agranulocytosis, and it is no longer considered a safe alternative [35]. Hydroxychloroquine was found to be associated with a high rate of skin toxic effects, together with increased relapse rate during follow-up, which prevented further evaluation [36].

Different retrospective studies highlighted that cyclophosphamide might be an option for refractory disease despite a high rate of side effects, ranging from 33% to 80%. A few patients received mycophenolate mofetil, and further studies are needed to better analyse the therapeutic potential of this drug for GCA [37]. An RCT evaluating the ability of cyclosporine A to induce remission and as a GCs-sparing agent gave negative results. A total of 26 of 29 patients in the cyclosporine A arm experienced side effects, so it should not be used for GCA [38].
Table 1. Results of randomised controlled trials evaluating immunosuppressants for giant cell arteritis (GCA).

| Author, Year       | Number of Patients | Disease Activity     | Drug Evaluated          | GC Therapy                                      | Main Primary Outcome                           | Result                                      |
|--------------------|--------------------|----------------------|-------------------------|------------------------------------------------|------------------------------------------------|---------------------------------------------|
| **Azathioprine**   |                    |                      |                         |                                                |                                                |                                             |
| De Silva et al., 1986 | 31                | GCA in remission     | Azathioprine 150 mg/day | GCs ≥ 5 mg/day Tapering 1 mg/month             | Not specified (studied GCs daily dose)           | Positive at month 12                       |
| **Dapsone**        |                    |                      |                         |                                                |                                                |                                             |
| Liozon et al., 1993 | 48                | New-onset GCA        | Dapsone 50–100 mg/day   | 0.7–1.0 mg/kg/day Tapering ≈ 14 months          | Relapses                                       | Positive but dapsone-related side effects  |
| **Hydroxychloroquine** |                 |                      |                         |                                                |                                                |                                             |
| Sailler et al., 2009 | 74                | New-onset GCA        | Hydroxychloroquine 400 mg/day | 0.7 mg/kg/day Tapering ≈ 16 months             | Remission > 3 month at the end of follow-up   | Negative and hydroxychloroquine-related side effects |
| **Methotrexate**   |                    |                      |                         |                                                |                                                |                                             |
| Spiera et al., 2001 | 21                | New-onset GCA        | MTX 7.5–20 mg/week      | >40 mg/day. Suggested tapering ≈ 4 months      | Cumulative dose of GCs at year 2               | Negative                                   |
| Jover et al., 2001  | 42                | New-onset GCA        | MTX 10 mg/week          | 60 mg/day. Tapering ≈ 6 months                 | Cumulative dose of GCs and relapses            | Positive                                   |
| Hoffman et al., 2002 | 98                | New-onset GCA        | MTX 0.15–0.25 mg/kg/week; max 15 mg/week | 1 mg/kg/day and <60 mg/day; alternate day tapering ≈ 6 months | Relapses                                       | Negative                                   |
| **Cyclosporine A** |                    |                      |                         |                                                |                                                |                                             |
| Schaufelberger et al., 2006 | 60 | New-onset GCA | CsA 2 mg/kg/day reduced or increased up to 3.5 mg/kg/day | Not specified | Cumulative dose of GCs and relapses | Negative. Numerous side effects |

CsA: cyclosporin A; GCs: glucocorticoids; MTX: methotrexate.
4. Biologic Agents

Immunohistology studies have detected tumour necrosis factor α (TNF-α) in inflamed arteries. From this observation and case reports, several RCTs of TNF-α versus a placebo evaluated the clinical value of targeting TNF-α or its receptor (Table 2). Despite the strong rationale, all three RCTs had negative findings and failed to demonstrate a benefit for remission induction [39], GC therapy withdrawal [40], relapse rate, or as a GCs-sparing therapy [41]. The efficacy and safety of blocking T-cell activation with abatacept was evaluated in an RCT: 49 patients received abatacept on days 1, 15 and 29 and during week 8, then 41 patients who were in clinical remission were randomised to continue monthly abatacept or switch to a placebo [42]. Despite an increased relapse-free survival with abatacept (48% vs. 31% at week 52, \( p = 0.049 \)), the phase 3 RCT was withdrawn (NCT03192969), although abatacept is still being evaluated versus placebo in another RCT for remission induction at year 1 (NCT04474847). In a study comparing TCZ, either IV or subcutaneous and abatacept subcutaneous, TCZ was found to more often induce vasculitis remission and to have a more important steroid sparing effect as compared to abatacept [43]. The weaker effect of abatacept might explain the phase 3 RCT withdrawal. Subcutaneous injections of ustekinumab at week 0, week 4 and then every 12 weeks was evaluated in 25 patients with refractory GCA [44]. In this cohort, the GC daily dose was reduced between baseline and week 52 and no patient experienced GCA relapse while under therapy, although five required a diminished interval between ustekinumab injections. In an open-label trial, ustekinumab was evaluated as an add-on therapy to treat active new-onset or relapsing disease [45]. The primary endpoint was the absence of relapse through week 52. Seven of 10 patients experienced relapse, and recruitment was stopped after the enrolment of 13 patients. The high rate of relapse might be due to the short and low-dose GC scheme used and may explain in part the disappointing results. A few patients with refractory GCA received anakinra, with seemingly good efficacy [46,47]. However, further data are required and this treatment cannot be recommended at this stage (ongoing trial: NCT02902731).

Since the early 1990s, interleukin 6 (IL-6) levels have been found to be associated with disease activity in GCA [48]. The potential interest of TCZ, a monoclonal antibody targeting the α-chain of the IL-6 receptor has emerged since 2010. After several case series [49], two RCTs confirmed that TCZ could have a major impact on relapse prevention or as a GCs-sparing agent [10,50]. Thirty patients with GCA were randomised 2:1 to receive IV TCZ monthly or placebo for 1 year: 85% of patients in the TCZ treatment arm were in remission at week 12 as compared with 40% in the placebo arm. Remission was maintained until the end of follow-up in the TCZ treatment arm, whereas only 20% of patients receiving the placebo were in remission at week 52 [50]. This striking improvement was confirmed and supported in the GIACTA study, a large phase 3 trial including 251 patients. More than half (56% and 53%) of patients receiving TCZ subcutaneously every week or every other week, respectively, showed sustained remission as compared with 18% and 14% of those receiving GCs only tapered over 26 or 52 weeks, respectively [10]. After this RCT, an open-label phase was continued, and the benefit of TCZ therapy remained significant for patients with new-onset or relapsing disease until the end of the 3-year follow-up [51]. Despite numerous relapses after TCZ withdrawal [49,52], the cumulative dose of GCs with TCZ treatment was considerably reduced. Safety concerns that might arise from a therapeutic strategy combining TCZ and GCs seem not to be justified in a selected population. A retrospective real-life study of 134 patients receiving TCZ only or combined with an IS agent, mainly MTX, suggested that treatment was safe and effective in unselected patients [53]. One-third of patients over 80 years old might experience mild to moderate TCZ-related side effects, which confirms the good safety profile of TCZ in the oldest patients [54]. In addition, for the first time, quality of life was improved with TCZ, as assessed by the Medical Outcomes Study 36-item Short Form Survey domain scores and was superior to the improvement observed in patients receiving GCs [55].
Table 2. Results of randomised controlled trials evaluating biologics during GCA.

| Author, Year           | Number of Patients | Disease Activity                          | Drug Evaluated                          | GC Therapy                                | Main Primary Outcome | Result   |
|------------------------|--------------------|-------------------------------------------|------------------------------------------|-------------------------------------------|----------------------|----------|
| Anti-TNF therapy       |                    |                                           |                                          |                                           |                      |          |
| Hoffman et al., 2007   | 44                 | New-onset GCA                             | Infliximab 5 mg/kg W0, 2 and 6 and every 8 weeks | Tapering < 6 months                       | Relapses at W22      | Negative |
| Martinez-Taboadda et al., 2008 | 17       | GCA in remission under GC > 10 mg/day. GC-related side effects | Etanercept 25 mg × 2/week (depending on initial daily dose) | Tapering < 4 months GC-free remission at M12 | GC-free remission at M12 | Negative |
| Seror et al., 2013     | 70                 | New-onset GCA                             | Adalimumab 40 mg at W2, 4, 6, 8, 10       | 0.7 mg/kg. Tapering ≈ 10 months            | Remission at W26 with GC < 0.1 mg/kg | Negative |
| Abatacept (CTLA4–Ig)   |                    |                                           |                                          |                                           |                      |          |
| Langford et al., 2017  | 49                 | New-onset or relapsing GCA Abatacept 10 mg/kg D1, 15, 29, 56 and GCs 40-60 mg/day/week for remission induction | 41 patients randomised at W12, abatacept 10 mg/kg/4 weeks | 20 mg/day at randomisation. Tapering until W28 | Relapse-free survival | Positive |
| Tocilizumab (IL-6 receptor inhibitor) |                    |                                           |                                          |                                           |                      |          |
| Villiger et al., 2016  | 30                 | New-onset or relapsing                    | Tocilizumab 8 mg/kg/month                | 1 mg/kg/day Tapering ≈ 9 months            | Remission at W12 with GCs 0.1 mg/kg. Normal ESR and CRP | Positive |
| Stone et al., 2017     | 251                | New-onset or relapsing                    | Tocilizumab 162 mg/week or 162 mg every other week | 20–60 mg/day. Tapering 26 or 52 weeks     | Prednisone-free remission at W52 | Positive |
| Mavrilimumab (GM-CSF receptor-α inhibitor) |                    |                                           |                                          |                                           |                      |          |
| Cid et al., 2020       | 70                 | New-onset or relapsing                    | Mavrilimumab 150 mg every other week     | 20–60 mg/day. Tapering 26 weeks            | Relapse at W26       | Positive |
| Secukinumab (IL-17A inhibitor) |                    |                                           |                                          |                                           |                      |          |
| Venhoff et al., 2021   | 52                 | New-onset or relapsing                    | Secukinumab 300 mg/week (5 doses) then 300 mg/4 week until W48 | 25–60 mg/day. Tapering 26 weeks            | Sustained remission at W28 | Positive |

CRP: C-reactive protein; CTLA4: cytotoxic T-lymphocyte-associated protein 4; D: day; ESR: erythrocyte sedimentation rate; GCs: glucocorticoids; GCA: giant cell arteritis; GM-CSF: Granulocyte-macrophage colony stimulating factor; Ig: immunoglobulin; IL: interleukin; M: month; TNF: tumor necrosis factor; W: week.
5. Future Perspectives

Following the progress in researching the pathophysiological pathways involved in GCA, several other molecules are currently being evaluated. Scarce reports suggest the potential interest of Janus kinase inhibitors [56]. In a proof-of-concept open-label study recruiting 15 patients, baricitinib 4 mg/day was found to be effective in patients with relapsing GCA. It allowed discontinuation of GC therapy in 13/14 patients at week 52 and was apparently well-tolerated despite the occurrence of adverse events in all but one patient [57]. The value of upadacitinib, a Janus kinase 1 and 1/3 inhibitor, is being evaluated in a multinational RCT to induce sustained remission at week 52 (NCT03725202). Apart from the theoretical interest of secukinumab, an anti–IL-17 monoclonal antibody, a case report of a patient with both psoriatic arthritis and GCA suggested its clinical value [58]. Secukinumab is being evaluated versus a placebo in a phase 2 RCT added to a 26-week GC tapering scheme to enable sustained remission at week 28 (NCT03765788). Among 52 randomised patients, 70.1% of those receiving secukinumab reached the primary endpoint as compared to 20.3% in the placebo arm group (late abstract L19, ACR 2021). Another RCT will evaluate guselkumab, an anti–IL-23 monoclonal antibody, versus a placebo added to a 26-week GC tapering scheme to enable a sustained GC-free remission at week 28 (NCT04633447). Granulocyte-macrophage colony stimulating factor has emerged as a key cytokine playing a role in GCA inflammatory vascular lesions. A phase 2 RCT versus a placebo showed that the subcutaneous injection of 150 mg of mavrilimumab every other week could increase the time to relapse at week 26. In total, 83.2% of patients receiving mavrilimumab and 49.9% of those receiving placebo showed sustained remission at week 26 (late abstract L06, ACR2020). Sarilumab, another IL-6 receptor inhibitor, was evaluated in a large phase 3 RCT (NCT03600805). Unfortunately, the COVID-19 pandemic outbreak led to early discontinuation of the trial after the enrolment of 83 patients. Preliminary results available at ClinicalTrials.gov suggest the efficacy of sarilumab, although the results should be interpreted with caution. Apart from neutropenia, no safety concern was identified.

6. Therapeutic Strategy and International Recommendations

Treatment with high-dose GC therapy allows for clinical and biological remission in patients with GCA. There are no evidence-based data to support the use of a higher initial dose of GCs for patients with specific manifestations. The improvement in visual manifestations seems related to the delay between symptoms and treatment rather than the GCs’ dose. In this context, high-dose IV methylprednisolone is considered the best treatment for patients with visual manifestations, on an expert opinion basis [11–14]. Unfortunately, only scarce findings can help identify patients who will experience relapse or will have GC-related side effects during follow-up. Therefore, combining GCs with an IS or biologic agent at the time of diagnosis is guided by the estimated risk associated with GC treatment. This is the ground-based approach proposed by European experts [11,13] and our team (Figure 1). It differs from the most recent recommendations established by US practitioners who advise a GCs-sparing agent in most patients and favour TCZ over MTX and other IS agents [14]. The youngest patients and those with large-vessel involvement may frequently experience relapse [4,8,59,60]. These patients who have clinical features overlapping with Takayasu arteritis may have some benefit from the initial prescription of GCs-sparing therapy at the time of diagnosis. Moreover, individuals > 75 years old and those with cardiovascular disease or diabetes might have more side effects from GC therapy [8]. The disease-related specific manifestations and medical history tend to help identify patients who require GCs-sparing therapy at the time of diagnosis (Figure 1).
treatment. This is the ground-based approach proposed by European experts [11,13] and our team (Figure 1). It differs from the most recent recommendations established by US practitioners who advise a GCs-sparing agent in most patients and favour TCZ over MTX [14]. The youngest patients and those with large-vessel involvement may frequently experience relapse [4,8,59,60]. These patients who have clinical features overlapping with Takayasu arteritis may have some benefit from the initial prescription of GCs-sparing therapy at the time of diagnosis. Moreover, individuals >75 years old and those with cardiovascular disease or diabetes might have more side effects from GC therapy [8]. The disease-related specific manifestations and medical history tend to help identify patients who require GCs-sparing therapy at the time of diagnosis (Figure 1).

Figure 1. Proposed algorithm for treating giant cell arteritis. GCs: glucocorticoids; MTX: methotrexate; TCZ: tocilizumab.

Previously, treatment was considered to last 18 to 24 months [12]; the recommended length was progressively decreased from 12 to 18 months [13] to an individually tailored protocol based on clinical symptoms and biological results [14]. This reduced length of treatment significantly differed from the European recommendations, advising against a rapid tapering regimen [11]. It is probably based on the indication of biologic and IS agents, which are considered the first-line therapy for most patients in the US guidelines [14] but is considered a rescue therapy for most patients in the European ones [11–13]. Of note, treatment length > 2 years and relapse is associated with GC-related side effects, which should prevent the undue use of GCs for treating only relapse [61,62]. Sight threatening relapses are extremely rare, whereas GC-related adverse events occur in most patients. We therefore recommend a 12–18 month treatment with GCs, and a reduced length may be considered in frailer patients.

Follow-up is based on regular clinical and biological evaluation. An increase in levels of inflammatory markers without any clinical signs suggestive of disease activity should not be considered a relapse and requires additional investigations, including searching for infection [14]. A consensus-based distinction between a major relapse defined by relapse with ischemic manifestations and minor relapse emerged in the European League Against Rheumatism recommendations [11]. Major and minor relapses differ in the proposed dose of GCs that should be used in association with IS or biologic agents: 40 to 60 mg/day for major relapses and the previously effective GCs’ dose for minor relapses. A retrospective study found that jaw claudication was the ischemic event in 44% of major relapses [63], which questions the implication in everyday patient care. Indeed, no additional data have been published to support that ocular manifestations, aortitis and limb ischemia are less responsive to standard therapy in patients with relapse. In contrast, vascular manifestations are well associated with further relapse during subsequent follow-up and
should encourage the prescription of an IS or biologic agent in these patients. Comparing GCA and rheumatoid arthritis management, some questions still need to be answered. Is there a benefit to introducing IS or biological therapy early in GCA course in terms of sustained remission induction or time to relapse [64]? In patients receiving GC add-on therapy, do we have to consider an increased administration interval and slow tapering of IS or biological therapy to prevent further relapses [65]?

7. Non-Immunosuppressive Therapy

The increased short-term risk of ischaemic events raises the question of vascular event prevention. Despite several retrospective studies, whether low-dose aspirin could confer a significant protection is unclear. Indeed, two retrospective studies demonstrated a significant decrease in vascular ischemic events in patients receiving antiplatelet therapy [66,67]. A meta-analysis suggested that low-dose aspirin may have a marginal benefit when combined with GCs at the initial phase of the disease [68]. Disregarding these data, recommendations have advised following international guidelines for vascular disease prevention without any specificity for individuals with GCA [11,13,14]. The value of anticoagulants is not well documented. Different studies evaluated statins as a GCs-sparing agent but did not find any clinical benefit [69,70].

Despite the increasing use of IS or biologic agents during GCA, there is no specific concern regarding treatment in this frail population following the COVID-19 pandemic. The main risk for severe SARS-CoV-2 infection arises from the age of patients and associated comorbidities. Unlike rituximab in patients with anti-neutrophil cytoplasm antibody-associated vasculitis, treatment with GCs, MTX or TCZ modestly increased COVID-19 severity [71]. The vaccination response might be impaired, and treatment risks should be carefully balanced with benefits from GC add-on treatments. Finally, polymyalgia rheumatica or GCA might develop soon after vaccination [72]. However, a fortuitous occurrence must be considered.

8. Conclusions

Major efforts have been made recently to develop GC-reduced therapeutic strategies in GCA. This work questions the value of GCs in the disease. Is it the feared treatment to avoid in this frail population? We acknowledge that a short GC therapy has a rapid effect on vasculitis control. Better defining which patients might benefit from alternative therapy is crucial to appropriately using each treatment within a safe and cost-effective strategy. TCZ has the strongest evidence as a GC add-on therapy in patients with newly diagnosed or relapsing GCA. In the future, head-to-head comparisons of biological therapies might be required to build an efficient therapeutic strategy in these patients. Available GC add-on therapies have a steroid sparing effect and reduce relapse occurrence but fail to cure GCA, warranting further research.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: A.R. received fees for medical boards from Chugai (<EUR 10,000).

Abbreviations

AZA azathioprine
GCs glucocorticoids
GCA giant cell arteritis
IL interleukin
IS immunosuppressant
References

1. Gonzalez-Gay, M.A.; Vazquez-Rodriguez, T.R.; Lopez-Diaz, M.J.; Miranda-Filloy, J.A.; Gonzalez-Juanatey, C.; Martin, J.; Llorca, J. Epidemiology of giant cell arteritis and polymyalgia rheumatica. *Arthritis Rheum.* 2009, 61, 1454–1461. [CrossRef] [PubMed]

2. Blockmans, D.; Bley, T.; Schmidt, W. Imaging for large-vessel vasculitis. *Curr. Opin. Rheumatol.* 2009, 21, 19–28. [CrossRef] [PubMed]

3. Spiera, R.; Unizony, S.H.; Bao, M.; Luder, Y.; Han, J.; Pavlov, A.; Stone, J.H. Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial. *Semin. Arthritis Rheum.* 2021, 51, 469–476. [CrossRef] [PubMed]

4. De Mornac, D.; Espitia, O.; Néel, A.; Connault, J.; Masseau, A.; Espitia-Thibault, A.; Artifoni, M.; Achille, A.; Wahbi, A.; Lacou, M.; et al. Large-vessel involvement is predictive of multiple relapses in giant cell arteritis. *Ther. Adv. Musculoskelet. Dis.* 2021, 13, 1759720X211009029. [CrossRef] [PubMed]

5. Birkhead, N.C.; Wagener, H.P.; Shick, R.M. Treatment of temporal arteritis with adrenal corticosteroids; results in fifty-five cases in which lesion was proved at biopsy. *J. Am. Med. Assoc.* 1957, 163, 821–827. [CrossRef]

6. Miloslavsky, E.M.; Naden, R.P.; Bijlsma, J.W.J.; Brogan, P.A.; Brown, E.S.; Brunetta, P.; Buttgerieit, F.; Choi, H.K.; DiCaire, J.-F.; Gelland, J.M.; et al. Development of a glucocorticoid toxicity index (GTI) using multicriteria decision analysis. *Ann. Rheum. Dis.* 2017, 76, 543–546. [CrossRef]

7. Proven, A.; Gabriel, S.E.; Oreces, C.; O’Fallon, W.M.; Hunder, G.G. Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcomes. *Arthritis Rheum.* 2003, 49, 703–708. [CrossRef]

8. Perrineau, S.; Ghersquiére, T.; Charles, P.; Paule, R.; Samson, M.; Gayraud, M.; Chauvin, A.; Terrier, B.; Guillevin, L.; Bonnotte, B.; et al. A French cohort of patients with giant cell arteritis: Glucocorticoid treatment and its associated side effects. *Clin. Exp. Rheumatol.* 2021, 39, Suppl. (129), 155–160. [CrossRef]

9. Mahr, A.D.; Jover, J.A.; Spiera, R.F.; Hernández-Garcia, C.; Fernández-Gutierrez, B.; Lavalley, M.P.; Merkel, P.A. Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data meta-analysis. *Arthritis Rheum.* 2007, 56, 2789–2797. [CrossRef]

10. Stone, J.H.; Tuckwell, K.; Dimonaco, S.; Klearman, M.; Aringer, M.; Blockmans, D.; Brouwer, E.; Cid, M.C.; Dasgupta, B.; Rech, J.; et al. Trial of tocilizumab in giant-cell arteritis. *N. Engl. J. Med.* 2017, 377, 317–328. [CrossRef]

11. Hellmich, B.; Agueda, A.; Monti, S.; Buttgerieit, F.; de Boysson, H.; Brouwer, E.; Cassie, R.; Cid, M.C.; Dasgupta, B.; Dejaco, C.; et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. *Ann. Rheum. Dis.* 2020, 79, 19–30. [CrossRef] [PubMed]

12. Bienvenu, B.; Ly, K.H.; Lambert, M.; Agard, C.; André, M.; Benhamou, Y.; Bonnotte, B.; de Boysson, H.; Espitia, O.; Fau, G.; et al. Management of giant cell arteritis: Recommendations of the French study group for large vessel vasculitis (GEFA). *Rev. Med. Interne* 2016, 37, 154–165. [CrossRef] [PubMed]

13. Mackie, S.L.; Dejaco, C.; Appenzeller, S.; Camellino, D.; Dufnner, C.; Gonzalez-Chiappe, S.; Mahr, A.; Mukhtyar, C.; Reynolds, G.; de Souza, A.W.S.; et al. British society for rheumatology guideline on diagnosis and treatment of giant cell arteritis: Executive summary. *Rheumatology* 2020, 59, 487–494. [CrossRef] [PubMed]

14. Maz, M.; Chung, S.A.; Abril, A.; Langford, C.A.; Greokil, M.; Guyatt, G.; Archer, A.M.; Conn, D.L.; Full, K.A.; Grayson, P.C.; et al. 2021 American college of rheumatology / vasculitis foundation guideline for the management of giant cell arteritis and takayasu arteritis. *Arthritis Rheumatol.* 2021, 73, 1349–1365. [CrossRef] [PubMed]

15. Hoffman, G.S. Giant cell arteritis. *Ann. Intern. Med.* 2016, 165, ITC65–ITC80. [CrossRef]

16. Diamantopoulos, A.P.; Haugeberg, G.; Lindland, A.; Myklebust, G. The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: Towards a more effective strategy to improve clinical outcome in giant cell arteritis? *Rheumatology* 2016, 55, 66–70. [CrossRef]

17. Monti, S.; Bartoletti, A.; Bellis, E.; Delvino, P.; Montecucco, C. Fast-track ultrasound clinic for the diagnosis of giant cell arteritis changes the prognosis of the disease but not the risk of future relapse. *Front. Med.* 2020, 7, 589794. [CrossRef]

18. Chevalet, P.; Barrier, J.H.; Pottier, P.; Magadur-Joly, G.; Pottier, M.A.; Hamidou, M.; Planchnon, B.; El Kouri, D.; Connnan, L.; Dupond, J.L.; et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: A one year followup study of 164 patients. *J. Rheumatol.* 2000, 27, 1484–1491.

19. Mazlumzadeh, M.; Hunder, G.G.; Easley, K.A.; Calamia, K.T.; Matteson, E.L.; Griffing, W.L.; Younge, B.R.; Weyand, C.M.; Goronzy, J.J. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: A double-blind, placebo-controlled, randomized prospective clinical trial. *Arthritis Rheum.* 2006, 54, 3310–3318. [CrossRef]

20. Dasgupta, B.; Borg, F.A.; Hassan, N.; Alexander, L.; Barracough, K.; Bourke, B.; Fulcher, J.; Hollywood, J.; Hutchings, A.; James, P.; et al. BSR and BHPR guidelines for the management of giant cell arteritis. *Rheumatology* 2010, 49, 1594–1597. [CrossRef]
21. Hunder, G.G.; Sheps, S.G.; Allen, G.L.; Joyce, J.W. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: Comparison in a prospective study. *Ann. Intern. Med.* 1975, 82, 613–618. [PubMed]

22. Hayreh, S.S.; Zimmerman, B.; Kardon, R.H. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. *Acta Ophthalmol. Scand.* 2002, 80, 355–367. [CrossRef] [PubMed]

23. González-Gay, M.A.; Blanco, R.; Rodríguez-Valverde, V.; Martínez-Taboada, V.M.; Delgado-Rodríguez, M.; Figueroa, M.; Uriarte, E. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: Predictors and response to treatment. *Arthritis Rheum.* 1998, 41, 1497–1504. [CrossRef] [PubMed]

24. Kyle, V.; Hazleman, B.L. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. *Ann. Rheum. Dis.* 1989, 48, 658–661. [CrossRef]

25. Martinez-Lado, L.; Calviño-Díaz, C.; Piñeiro, A.; Dierssen, T.; Vazquez-Rodriguez, T.R.; Miranda-Filloy, J.A.; Lopez-Diaz, M.J.; Blanco, R.; Llorca, J.; González-Gay, M.A. Relapses and recurrences in giant cell arteritis: A population-based study of patients with biopsy-proven disease from Northwestern Spain. *Medicine* 2011, 90, 186–193. [CrossRef]

26. Mendel, A.; Ennis, D.; Carette, S.; Pagnoux, C. Assessment of glucocorticoid tapering in large vessel and anti-neutrophil cytoplasmic antibody-associated vasculitides. *Clin. Exp. Rheumatol.* 2021, 39 (Suppl. 129), 119–124.

27. Spierer, R.F.; Mitnick, H.J.; Kupersmith, M.; Richmond, M.; Spierer, H.; Peterson, M.G.; Paget, S.A. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). *Clin. Exp. Rheumatol.* 2001, 19, 495–501.

28. Hoffman, G.S.; Cid, M.C.; Hellmann, D.B.; Guillemin, L.; Stone, J.H.; Schousboe, J.; Cohen, P.; Calabrese, L.H.; Dickler, H.; Merkel, P.A.; et al. A Multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. *Arthritis Rheum.* 2002, 46, 1309–1318. [CrossRef]

29. Jover, J.A.; Hernández-García, C.; Morado, I.C.; Vargas, E.; Bañares, A.; Fernández-Gutiérrez, B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. *Ann. Intern. Med.* 2001, 134, 106–114.

30. Gérard, A.-L.; Simon-Tilliaux, N.; Yordanov, Y.; Cacoub, P.; Tubach, F.; Saadoun, D.; Dechartres, A. Efficacy and safety of steroid-sparing treatments in giant cell arteritis according to the glucocorticoids tapering regimen: A systematic review and meta-analysis. *Eur. J. Intern. Med.* 2021, 88, 96–103. [CrossRef]

31. Diamantopoulos, A.P.; Hetland, H.; Myklebust, G. Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: A case series. *BioMed Res. Int.* 2013, 2013, 120638. [PubMed]

32. Tengesdal, S.; Diamantopoulos, A.P.; Myklebust, G. Leflunomide versus methotrexate in treatment of giant cell arteritis: Comparison of efficacy, safety, and drug survival. *Scand. J. Rheumatol.* 2019, 48, 333–335. [CrossRef] [PubMed]

33. De Silva, M.; Hazleman, B.L. Azathioprine in giant cell arteritis/polymyalgia rheumatica: A double-blind study. *Ann. Rheum. Dis.* 1986, 45, 136–138.

34. Ly, K.H.; Dalmay, F.; Gondran, G.; Palat, S.; Bezanahary, H.; Cypierre, A.; Fauchais, A.-L.; Liozon, E. Steroid-sparing effect and toxicity of dapsone treatment in giant cell arteritis: A single-center, retrospective study of 70 patients. *Medicine* 2016, 95, e4974. [CrossRef] [PubMed]

35. Liozon, F.; Vidal, E.; Barrier, J. Does dapsone have a role in the treatment of temporal arteritis with regard to efficacy and toxicity? *Clin. Exp. Rheumatol.* 1993, 11, 694–695. [PubMed]

36. Sailler, L.; Pugnet, G.; Bienvenu, B. Treatment of giant cell arteritis. *Rev. Med. Interne* 2013, 34, 431–437. [CrossRef] [PubMed]

37. Sciascia, S.; Piras, D.; Baldovino, S.; Russo, A.; Naretto, C.; Rossi, D.; Alpa, M.; Roccatello, D. Mycophenolate mofetil as steroid-sparing treatment for elderly patients with giant cell arteritis: Report of three cases. *Aging Clin. Exp. Res* 2016, 24, 273–277. [CrossRef] [PubMed]

38. Schaufelberger, C.; Möllby, R.; Udshammer, A.; Bratt, J.; Nordborg, E. No additional steroid-sparing effect of cyclosporine A in giant cell arteritis. *Scand. J. Rheumatol.* 2006, 35, 327–329. [CrossRef]

39. Seror, R.; Baron, G.; Hachulla, E.; Debandt, M.; Larroche, X.; Maurier, F.; de Wazieres, B.; Quéré, N.; Vial, E.; et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: Results of a multicentre randomised controlled trial. *Ann. Rheum. Dis.* 2014, 73, 2074–2081. [CrossRef]

40. Martínez-Taboada, V.M.; Rodríguez-Valverde, V.; Carreño, L.; López-Longo, J.; Figueroa, M.; Belzunegui, J.; Mola, E.M.; Bonilla, G. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. *Ann. Rheum. Dis.* 2008, 67, 625–630. [CrossRef]

41. Hoffman, G.S.; Cid, M.C.; Redt-Zagar, K.E.; Merkel, P.A.; Weyard, C.M.; Stone, J.H.; Savarani, C.; Xu, W.; Visvanathan, S.; Rahman, M.U.; et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: A randomized trial. *Ann. Intern. Med.* 2007, 146, 621–630.

42. Langford, C.A.; Cuthbertson, D.; Ytterberg, S.R.; Khalidi, N.; Monach, P.A.; Carette, S.; Seo, P.; Moreland, L.W.; Weisman, M.; Koeing, C.L.; et al. A Randomized, double-blind trial of abatacept (CTLA4-IG) for the treatment of giant cell arteritis. *Arthritis Rheumatol.* 2017, 69, 837–845. [CrossRef] [PubMed]

43. Rossi, D.; Cecchi, I.; Sciascia, S.; Naretto, C.; Alpa, M.; Roccatello, D. An agent-to-agent real life comparison study of tocilizumab versus abatacept in giant cell arteritis. *Clin. Exp. Rheumatol.* 2021, 39 (Suppl. 129), 125–128. [PubMed]

44. Conway, R.; O’Neill, L.; O’Flynn, E.; Gallagher, P.; McCarthy, G.M.; Murphy, C.C.; Veale, D.J.; Fearon, U.; Molloy, E.S. Ustekinumab for the treatment of refractory giant cell arteritis. *Ann. Rheum. Dis.* 2016, 75, 1578–1579. [CrossRef] [PubMed]
68. Martínez-Taboada, V.M.; López-Hoyos, M.; Narvaez, J.; Muñoz-Cacho, P. Effect of antiplatelet/anticoagulant therapy on severe ischemic complications in patients with giant cell arteritis: A cumulative meta-analysis. *Autoimmun. Rev.* 2014, 13, 788–794. [CrossRef]

69. García-Martínez, A.; Hernández-Rodriguez, J.; Grau, J.M.; Cid, M.C. Treatment with statins does not exhibit a clinically relevant corticosteroid-sparing effect in patients with giant cell arteritis. *Arthritis Rheum.* 2004, 51, 674–678. [CrossRef] [PubMed]

70. Narváez, J.; Bernad, B.; Gómez-Vaquero, C.; García-Gómez, C.; Roig-Vilaseca, D.; Juanola, X.; Rodriguez-Moreno, J.; Nolla, J.M.; Valverde, J. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. *Clin. Exp. Rheumatol.* 2008, 26, S57–S62. [PubMed]

71. Curtis, J.R.; Johnson, S.R.; Anthony, D.D.; Arasaratnam, R.J.; Baden, L.R.; Bass, A.R.; Calabrese, C.; Gravallese, E.M.; Harpaz, R.; Sadun, R.E.; et al. American college of rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: Version 1. *Arthritis Rheumatol.* 2021, 73, 1093–1107. [CrossRef] [PubMed]

72. Cadiou, S.; Perdriger, A.; Ardois, S.; Albert, J.-D.; Berthoud, O.; Lescoat, A.; Guggenbuhl, P.; Robin, F. SARS-CoV-2, Polymyalgia rheumatica and giant cell arteritis: COVID-19 vaccine shot as a trigger? Comment on: “Can SARS-CoV-2 trigger relapse of polymyalgia rheumatica?” By Manzo et al. *Jt. Bone Spine* 2022, 89, 105282. [CrossRef]